Clinical trial
Randomized, 2-way Crossover Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg and Lamisil® 250 mg Tablets in Healthy Subjects Under Fasting Conditions.
NCT01286688 is registered in ClinicalTrials.gov with Dr. Reddy's Laboratories Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, 2-way Crossover Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg and Lamisil® 250 mg Tablets in Healthy Subjects Under Fasting Conditions.
- Lead sponsor
- Dr. Reddy's Laboratories Limited
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 31, 2002
- Completion date
- March 31, 2002
- Enrollment
- 36 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
fasting